AJMC® in the Press, April 2, 2021

An article by The Heartland Institute referenced a study published in the December 2012 issue of The American Journal of Managed Care^® (AJMC^®) titled “Personalized Preventive Care Leads to Significant Reductions in Hospital Utilization.” The study assessed the impact of the MDVIP personalized preventive care model on hospital utilization and found that MDVIP members’ utilization rates were substantially lower than those of nonmembers.

Posted on einnews.com, a press release cited an article published in an August 2017 supplement to AJMC^®. The article, “Overview of Atopic Dermatitis,” noted that atopic dermatitis is a multifaceted, chronic relapsing inflammatory skin disease that is the most common skin disease in children, affecting approximately 15% to 20% of children and 1% to 3% of adults.

A piece by pharmiweb.com spotlighted an article published on AJMC.com, the website of AJMC^®. The article, “ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit,” noted that while the CAR-T cell therapies isagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may be high in price, a report by ICER finds that the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life-year.